Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3667361 | 0.97 | HDAC2 (0.57) | SMN1; SMN2HPGDTSHRHDAC2HDAC1 | |
| SCHEMBL3662978 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2HPGDTSHRHDAC2HDAC1 | |
| SCHEMBL3663937 | 0.92 | HDAC2 (0.57) | SMN1; SMN2HPGDTSHRHDAC2HDAC1 | |
| SCHEMBL3661428 | 0.91 | HDAC2 (0.58) | SMN1; SMN2HPGDTSHRHDAC2HDAC1 | |
| SCHEMBL3660189 | 0.91 | HDAC2 (0.58) | SMN1; SMN2HPGDTSHRHDAC2HDAC1 | |
| SCHEMBL3665046 | 0.90 | HDAC2 (0.59) | SMN1; SMN2HPGDTSHRHDAC2HDAC1 | |
| SCHEMBL3662627 | 0.90 | HDAC2 (0.54) | SMN1; SMN2HPGDTSHRHDAC2HDAC1 | |
| SCHEMBL3664180 | 0.90 | HDAC2 (0.61) | SMN1; SMN2HPGDTSHRHDAC2HDAC1 | |
| SCHEMBL3662942 | 0.90 | HDAC2 (0.56) | SMN1; SMN2HPGDTSHRHDAC2HDAC1 | |
| SCHEMBL3663812 | 0.89 | HDAC2 (0.57) | SMN1; SMN2HPGDTSHRHDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2010-11-18 | — | — | US | claimed |
| EP-2220066-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | Gilead Colorado, Inc. (US) | 2010-08-25 | — | — | EP | claimed |
| WO-2009079391-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2009-06-25 | — | — | WO | claimed |
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2220066-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | Gilead Colorado, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009079391-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC7, HDAC5 | SMN1; SMN2 2074/4885HPGD 742/4885TSHR 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.